Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor

Matthias Holdhoff(Johns Hopkins University), Philipp le Coutre(Charité - Universitätsmedizin Berlin)

Blood Cells Molecules and Diseases

February 1, 2005

10.1016/j.bcmd.2004.11.006

Cited by 81

Related Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

|Blood|2007|744

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas

|Journal of Neuro-Oncology|2019|127